-Sai Life Sciences opens a new discovery biology facility at its integrated R&D campus located in Hyderabad (India)
HYDERABAD, India, Aug. 18, 2021 / PRNewswire / – Sai Life Sciences, a organization of research, development and contract manufacturing (CRO-CDMO) world leader, announced today the opening of a new biology facility in its integrated R&D campus in Hyderabad, India. The installation marks an important milestone on the way to position itself as a differentiated actor in the Biology of Discovery.
–
When making the announcement, Krishna Kanumuri, CEO and CEO of Sai Life Sciences, stated: “The new facility marks the culmination of a journey we began two years ago of creating differentiated value for our discovery customers through an integrated delivery model in Boston and Hyderabad. By bringing the best in talent, technology, complementary services and efficiency, we are confident of delivering unique value to our clients and are ready to take on integrated discovery mandates, at scale. ”
Continuing with the aggressive growth of the company in its biology services, new and modern facilities house expanded biology services in vitro and in vivo, DMPK, toxicology and a vivarium. The facilities increase both their competencies and their ability to deploy cutting-edge technologies and platforms to accelerate integrated drug discovery programs.
Integrated delivery model Boston–Hyderabad
Sai Life Sciences has been constantly growing its biology capabilities to complement its strong foundation in medical chemistry, DMPK and toxicology to support their clients throughout the entire drug discovery journey, from target identification and validation to IND. In 2019, the company opened its first international R&D facility with a biology laboratory in Boston, USA. The laboratory Boston Biology Lab is designed to provide the region’s biotech and startup companies with biology services to address exploratory and custom biology needs.
The integrated biology service delivery model aims to offer customers an optimal solution in terms of experience, speed and cost. In this model, critical exploratory work involving close collaboration with clients is carried out in the laboratory of Boston, after which, the established trials are technologically transferred to Hyderabad to achieve higher performance. Rapid and seamless technology transfer between centers is achieved through a unified global organization and an infrastructure that accommodates both centers. Encouraged by the initial success of the integrated model Boston–Hyderabad, the company plans to expand its capacity at both locations in the coming months.
The discovery services of the company support a wide range of global innovative companies, from startups to large pharmaceutical companies, in a diverse set of therapeutic areas including oncology, the central nervous system, antivirals and inflammation, among others. With a strong history of long-standing customer relationships of over 10 years on average, Sai Life Sciences has conducted more than 35 programs across different clinical phases (from IND to Phase III), with an average response time from the success / leader up to 18-month-old candidate.
The new facility culminates the company’s journey to unify its discovery, early and late-stage development and clinical supply capabilities on a single 13-acre campus that is home to more than 1,000 scientists, offering integrated value at scale.
About Sai Life Sciences
Sai Life Sciences is a Full service CRO-CDMO working with innovative pharmaceutical and biotech companies around the world to accelerate the discovery, development and commercialization of complex small molecules. For more than two decades, Sai Life Sciences has consistently provided high-quality, cost-effective solutions to its diverse customers, including small, medium and large pharmaceutical and biotech companies. Currently, it has more than 2,200 employees spread over its facilities in the India, United Kingdom and United States. https://www.sailife.com
–
–
